Zargari Mehryar, Maadi Negar, Rezapour Maysam, Bagheri Abouzar, Fallahpour Samane, Nosrati Mani, Mahrooz Abdolkarim
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Clinical Biochemistry and Medical Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Adv Biomed Res. 2024 Jul 29;13:38. doi: 10.4103/abr.abr_391_22. eCollection 2024.
This study aimed to assess the serum activity of paraoxonase 1 (PON1) in patients with coronary artery disease (CAD) based on two genetic variants including the -108C/T variant in the promoter region and the rs3735590 variant in the binding site of miR-616 at the 3'-UTR of the PON1 gene.
A total of 140 subjects who exhibited clinical symptoms of CAD underwent diagnostic coronary angiography. The patients with CAD were further categorized into two groups: single-vessel disease (SVD) and multi-vessel disease (MVD). The study variants were genotyped using the restriction fragment length polymorphism (RFLP) technique after polymerase chain reaction amplification.
After adjusting for age, gender, body mass index, metformin, and statin usage, a significant association was observed between the -108C/T variant and PON1 activity ( < 0.001). In the sub-groups of both SVD and MVD, individuals with the TC+CC genotypes exhibited significantly higher PON1 activity compared to TT homozygotes ( = 0.001 for SVD and = 0.01 for MVD). As for the rs3735590 variant, individuals with the A allele (GA+AA genotypes) had higher PON1 activity compared to those with the GG genotype in both the SVD and MVD groups, although the results did not reach statistical significance.
Our study findings indicate a significant decrease in PON1 activity among patients with obstructive CAD. Notably, our results suggest that the -108C/T variant exerts a greater influence on PON1 activity compared to the rs3735590 variant. These findings highlight the crucial role of the -108C/T variant in modulating PON1 activity within the context of atherosclerosis.
本研究旨在基于两种基因变异评估冠心病(CAD)患者血清对氧磷酶1(PON1)的活性,这两种基因变异分别为启动子区域的-108C/T变异以及PON1基因3'-UTR处miR-616结合位点的rs3735590变异。
共有140例出现CAD临床症状的受试者接受了诊断性冠状动脉造影。CAD患者进一步分为两组:单支血管病变(SVD)和多支血管病变(MVD)。在聚合酶链反应扩增后,使用限制性片段长度多态性(RFLP)技术对研究变异进行基因分型。
在调整年龄、性别、体重指数、二甲双胍和他汀类药物使用情况后,观察到-108C/T变异与PON1活性之间存在显著关联(<0.001)。在SVD和MVD亚组中,与TT纯合子相比,TC+CC基因型个体的PON1活性显著更高(SVD组为=0.001,MVD组为=0.01)。至于rs3735590变异,在SVD和MVD组中,A等位基因(GA+AA基因型)个体的PON1活性均高于GG基因型个体,尽管结果未达到统计学显著性。
我们的研究结果表明,阻塞性CAD患者的PON1活性显著降低。值得注意的是,我们的结果表明,与rs3735590变异相比,-108C/T变异对PON1活性的影响更大。这些发现突出了-108C/T变异在动脉粥样硬化背景下调节PON1活性中的关键作用。